Omeros eyes first approval for combo eye drug; MorphoSys plans jump into immunotherapy work;

@FierceBiotech: Industry Voices: The Zero-Person Biotech Company. Item | Follow @FierceBiotech

@JohnCFierce: Biotech's IPO boom extends its streak through a blistering July. Report | Follow @JohnCFierce

@RyanMFierce: Didn't take the lawyers long to start fishing for angry Optimer shareholders after Cubist buyout announced Tuesday. Release | Follow @RyanMFierce

@EmilyMFierce: NIH team sees diabetes drug as a possible tool for extending life. Story | Follow @EmilyMFierce

> Seattle-based Omeros has filed an NDA on a combo eye drug, looking for its first approval after 20 years in business. Xconomy reports

> MorphoSys says it plans to use part of its $252 million cash hoard on new R&D work related to immunotherapies. More

Transition Therapeutics is raising $21 million through the sale of securities. Report

> Iroko Pharmaceuticals has pulled its IPO, citing market conditions. Story

Medical Device News

@FierceMedDev: Trending on FierceMedicalDevices.com: Covidien watches profits slide after kicking drugs. Article | Follow @FierceMedDev

@MarkHFierce: House Republican freshmen are pressing hard for a vote on a device tax repeal bill. Item | Follow @MarkHFierce

@DamianFierce: Now the Senate is getting in on the push to spare FDA user fees from sequester cuts. Story | Follow @DamianFierce

@MichaelGFierce: Trending on FierceDrugDelivery.com: Swedish team creates 'impossible' record-breaking drug delivery material. Article | Follow @MichaelGFierce

> Smith & Nephew has $1.5B and eyes on M&A. More

> J&J's DePuy, fearing fracture or limb-loss risks, recalls orthopedic implant part. News

> Report: ICU Medical nears sale that could top $1B. Article

Pharma News

@FiercePharma: Tension rises for pharma in China as court reportedly fines J&J, officials visit Sanofi. ICYMI yesterday | Follow @FiercePharma

@CarlyHFierce: More bribery allegations in China, these ones against Baxter (and just now surfacing from last year). News | Follow @CarlyHFierce

> 'Brazil generics issue' costs Sanofi nearly as much as patent losses. News

> Indian challenge to GSK's Tykerb comes from Fresenius. Article

> Teva earnings come up short and path to future rockier than before. Story

And Finally… Two Saudi health workers were diagnosed with mild cases of Middle East Respiratory Syndrome, which has been stoking fears of a pandemic. Story

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.